

## PRESS RELEASE

Stockholm, Sweden, 3 February 2022

### **AnaCardio raises SEK 33 million for development of a novel therapy for heart failure**

AnaCardio today announced the completion of a fundraising round of 33 MSEK. The funds will be used to progress clinical development of its lead asset in heart failure. The capital injection is comprised of a convertible loan granted by Karolinska Development AB, LLD Nybohov Invest AB and Fredrik and Ann-Helene Ljungström.

*“We are pleased that these prominent investors want to continue supporting AnaCardio on its journey to improve the treatment options for heart failure patients. With this capital injection we are on-track to progress with our clinical plans for our lead asset AC01”* says Patrik Strömberg, CEO.

#### About AnaCardio

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at [www.anacardio.com](http://www.anacardio.com).

For further information, please contact

Patrik Strömberg, CEO

Telephone: +46 704 156 159

E-mail: [Patrik.stromberg@anacardio.com](mailto:Patrik.stromberg@anacardio.com)